NASDAQ:CRMD CorMedix Q2 2026 Earnings Report $7.53 +0.04 (+0.53%) Closing price 07/31/2026 04:00 PM EasternExtended Trading$7.52 -0.01 (-0.13%) As of 07/31/2026 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast CorMedix EPS ResultsActual EPSN/AConsensus EPS $0.26Beat/MissN/AOne Year Ago EPSN/ACorMedix Revenue ResultsActual RevenueN/AExpected Revenue$96.04 millionBeat/MissN/AYoY Revenue GrowthN/ACorMedix Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateThursday, August 13, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile CorMedix Earnings HeadlinesCorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026July 29, 2026 | globenewswire.comCormedix Restructures Leadership, Expands Operating and Commercial RoleJuly 2, 2026 | tipranks.comOne signature away. Expected within months.On May 21, 2026, a federal bank board unanimously approved a nearly $3 billion loan to build a gold mine on American soil. Congress had 25 days notice and raised no objections. The company's own filings cite substantial support and partnership from the Department of War. Alongside gold, the deposit holds a second metal China has banned from export to the U.S., the only domestic reserve of its kind. The company is roughly one fiftieth the size of Newmont. | Behind the Markets (Ad)CorMedix, Inc. Reports Progress on LOCK- IT 100 Data Review and Appoints Paul Chew as Consultant Advisor CMOJune 29, 2026 | finance.yahoo.comCorMedix Shareholders Reject Governance Changes at Annual MeetingJune 24, 2026 | tipranks.comCorMedix (CRMD) Stock Could Be 27.8% Undervalued After Q1 Results And Raised OutlookJune 17, 2026 | finance.yahoo.comSee More CorMedix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CorMedix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CorMedix and other key companies, straight to your email. Email Address About CorMedixCorMedix (NASDAQ:CRMD). is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers. In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures. The company is engaged in clinical and regulatory activities designed to support product labeling updates and broader patient access. Collaborative partnerships with dialysis providers and distributors help position CorMedix to deliver its therapies into established treatment settings. Founded in the mid-2000s and headquartered in Piscataway, New Jersey, CorMedix operates with a lean corporate structure that leverages external manufacturing and distribution networks. The company’s senior management team is led by President and Chief Executive Officer Craig Fraser, who brings more than 30 years of experience in the biopharmaceutical industry. CorMedix continues to pursue regulatory milestones and commercial arrangements that aim to expand its reach across North America, Europe and select emerging markets.View CorMedix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/27- 07/31Chevron’s Strong Quarter Shows Why It Still Leads the Energy SectorAmazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull CaseApple’s Record Quarter Could Not Outrun Its Guidance ProblemPopular’s Earnings Beat Shows Why This Bank Stock Keeps ClimbingMicrosoft Just Flipped the AI Spending Narrative OvernightEveryone’s Focused on China—But That’s Not ASML’s Biggest Risk Upcoming Earnings Booking (8/3/2026)Marriott International (8/3/2026)Diamondback Energy (8/3/2026)ONEOK (8/3/2026)Williams Companies (8/3/2026)Mitsubishi UFJ Financial Group (8/3/2026)Vertex Pharmaceuticals (8/3/2026)Palantir Technologies (8/3/2026)Spotify Technology (8/4/2026)SpaceX (8/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
